AR and adenocarcinoma: Neuroendocrine differentiation is a mechanism of resistance to AR-targeted therapy, mediated by lineage plasticity, the process through which AR-dependent adenocarcinoma cells undergo a phenotypic switch to new AR-independent phenotypes, called treatment-emergent neuroendocrine prostate cancer (t-NEPC) [11].